AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01142596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
Study NCT01142596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
Study NCT02976454 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided Self-Help Obesity Treatment
Description: Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
Study NCT02976454 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family-based behavioral obesity treatment
Description: Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
Study NCT02019927 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcorneal Electrical Stimulation
Description: The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
Study NCT02019927 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham
Study NCT01999270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)~Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider.
Study NCT01999270 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
Study NCT01999270 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDOPA-PET/MRI imaging
Description: FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
Study NCT02434939 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose ketamine
Description: Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
Study NCT02434939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
Study NCT03457363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DTM will be add above NC
Description: After oxygenation by classical nasal cannula, the DTM will be place above NC
Study NCT02998463 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: skin-to-skin facilitating garment
Description: Fabric garment designed to accommodate term neonates having skin-to-skin contact.
Study NCT01183806 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivastigmine
Description: All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
Study NCT01183806 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine
Description: All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
Study NCT01183806 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training program
Description: Exercise training program
Study NCT03457363 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DTM will be add above NC
Description: After oxygenation by classical nasal cannula, the DTM will be place above NC
Study NCT03872570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: intravenous administration
Study NCT03872570 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: intravenous administration
Study NCT02859363 — intervention group
Intervention type: GENETIC
Intervention: 26 common Fabry mutation types in Taiwan
Description: Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
Study NCT01426763 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CINRYZE with rHuPH20
Study NCT02926976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone with Clozapine
Description: Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study NCT02926976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole with Clozapine
Description: Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study NCT02926976 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium valproate with Clozapine
Description: sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study NCT02926976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: modified electroconvulsive therapy(MECT) with Clozapine
Description: modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study NCT00574197 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate Sodium
Description: 1440mg/day (720mg by mouth, twice a day)
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone 3 mg
Description: Participants will receive 3 mg oral risperidone tablets once daily for up to one Week.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 50 mg eq.
Description: Participants will receive 50 mg eq. PP1M intramuscular injection for 17 Weeks.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 75 mg eq.
Description: Participants will receive 75 mg eq. PP1M intramuscular injection for 17 Weeks.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 100 mg eq.
Description: Participants will receive 100 mg eq. PP1M intramuscular injection for 17 Weeks.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 150 mg eq.
Description: Participants will receive 150 mg eq. PP1M intramuscular injection for 17 Weeks.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 175 mg eq.
Description: Participants will receive 175 mg eq. PP3M intramuscular injection for 24 Weeks.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 263 mg eq.
Description: Participants will receive 263 mg eq. PP3M intramuscular injection for 24 Weeks.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 350 mg eq.
Description: Participants will receive 350 mg eq. PP3M intramuscular injection for 24 Weeks.
Study NCT03713658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate 525 mg eq.
Description: Participants will receive 525 mg eq. PP3M intramuscular injection for 24 Weeks.
Study NCT01084655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-700
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Study NCT01084655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: TAK-700 with docetaxel and prednisone on a continuous schedule.
Study NCT02926976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic seizure therapy(MST) with Clozapine
Description: Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
Study NCT02926976 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: clozapine
Description: clozapine may be used in the treatment of treatment-resistant schizophrenia
Study NCT03821389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NIOD Frequencer
Description: NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
Study NCT03821389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NIOD Frequencer
Description: NIOD will be implemented on four different parts of the chest walls, 3 minutes for each part and 12 minutes in total per each session. Left and right front and posterior chest walls will be stimulated (Figure1), particularly, on the anterior chest, intercostal spaces 1-2 above nipple line and lateral side of the midclavicular line 1-2 below intercostal spaces. The intensity of the NIOD can be selected between 80-100%, which is prespecified on the machine.
Study NCT03275129 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Ultrasound assessment of heart and lungs
Description: Patients will receive an ultrasound assessment of their heart and lungs.
Study NCT04250441 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Transcranial Ultrasound
Description: The FDA has determined that power intensity limits of 720 mW/cm squared at 2 megaHertz is safe for clinical use; the proposed equipment works within these parameters. Furthermore, monitoring sessions up to one hour as proposed in this study are routinely used in patients even with acute brain injury at 2 megaHertz without any reports of complications induced by the ultrasound device. No brain heating, cavitation or bleeding has been identified with the proposed equipment and protocol. For each individual safety can be followed by performing a selective mental status exam at each session completion.
Study NCT00256451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 50 mg/day for two days prior to the alcohol challenge session
Study NCT00256451 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone
Description: 50 mg/day for two days prior to the alcohol challenge session
Study NCT00256451 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo pills
Study NCT00256451 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alcohol
Description: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Study NCT00256451 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: alcohol
Description: 190 proof alcohol prepared to 11% volume mixed with fruit juice.
Study NCT00256451 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sham alcohol
Description: non-alcoholic placebo alcohol
Study NCT00256451 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham alcohol
Description: non-alcoholic placebo alcohol
Study NCT04079803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Oral placebo tablet
Study NCT04079803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam 100 mg tablet
Description: Simufilam 100 mg oral tablet
Study NCT04079803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simufilam 50 mg oral tablet
Description: Simufilam 50 mg oral tablet
Study NCT03975166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test Product
Description: 2 inhalations in one study period
Study NCT03975166 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference Product
Description: 2 inhalations in one study period
Study NCT03353350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efpeglenatide (SAR439977)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT03353350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT04660266 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Liver Ultrasound
Description: liver ultrasound examination, including gray-scale and seven Doppler examination
Study NCT03030703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phytic acid
Description: 350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
Study NCT01525719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: 10 mg everolimus
Study NCT04256382 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dementia pain care education
Description: Participants are educated about dementia pain care.
Study NCT04256382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dementia care education
Description: Participants are educated about dementia pain care.
Study NCT04572412 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Low dose Radiotherapy
Description: External Beam irradiation, single fraction of 0.5Gy, to be delivered within 48 hours of enrolment to study. With field to cover as close to lung edges as AP/PA technique allows.~A further 0.5GY to the thorax given up to 96 hours apart from first fraction is permitted, if a patient had either (a) responded to the first dose but then deteriorated, however remaining better than baseline level or (b) stabilized after first dose but not fully improved.
Study NCT02011087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bioelectric impedance analysis
Description: Undergo bioelectric impedance analysis
Study NCT04532203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAR-T cells
Description: Each subject receive CAR T-cells by intravenous infusion
Study NCT04532203 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ommaya Reservoir
Description: Surgical catheter placement into the fourth ventricle of the brain
Study NCT01535755 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: protocol
Description: In this group, the patients were weaned as the protocol.
Study NCT01535755 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: physician's orders
Description: In this group, the patients were weaned as the clinicians' order.
Study NCT02225951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nutritional product
Study NCT02225951 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard breakfast according to ADA recommendations
Study NCT01596621 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine hydrochloride
Description: Bendamustine will be be administered per dose and schedule specified in the arm description.
Study NCT00839657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Genotype-guided dosing algorithm for warfarin
Description: Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
Study NCT00839657 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical-guided dosing algorithm for warfarin
Description: Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
Study NCT03738345 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HFNC flow
Description: HFNC flow will be titrated based on the hospital's policy or protocol for hypoxemic patients and research protocol for healthy volunteers
Study NCT04283331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proparacaine Ophthalmic
Description: Each subject will have one eye randomized to receive a bandage contact lens soaked in anesthetic solution (proparacaine hydrochloride 0.5%) and the following eye will serve as a control and receive a bandage soft contact lens soaked in balanced salt solution, which is the current standard of care for PRK.
Study NCT03307759 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Pembrolizumab
Study NCT03307759 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy (SABR)
Description: Radiotherapy
Study NCT02237313 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: psychological support and therapeutic education program
Study NCT01614535 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
Description: Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
Study NCT01614535 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence
Description: Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
Study NCT00421707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW876008
Study NCT00421707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GW876008
Study NCT00421707 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03466996 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group
Description: More frequent follow up with face to face interaction.
Study NCT03466996 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care group
Description: Transition goal setting during annual follow up.
Study NCT01498367 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring of patients with diabetes type 2
Description: Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
Study NCT04262817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine form
Description: participants will receive 36mg/ml nicotine salt and freebase nicotine
Study NCT04262817 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-cigarette experimental flavor
Description: Participants will receive menthol and tobacco flavored e-cigarettes
Study NCT01948908 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal midazolam
Description: Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
Study NCT02705560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cow´s milk (3.9% fat, pasteurized)
Description: 600 ml full fat milk (organic, pasteurized, 400 kcal)
Study NCT02705560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: hard, yellow cheese
Description: 100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)